ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS IN BRAZIL

A COHORT

Authors

  • Yara Ceres e Silva Ferreira Lima Hospital Universitário Walter Cantidio
  • Beatrice Araujo Duarte
  • Fernando Barroso Duarte Filho
  • Isabella Araujo Duarte
  • Joao Vitor Araujo Duarte
  • Ana Claudia Ferrari dos Santos
  • Vergílio Antônio Rensi Colturato
  • Mair Pedro de Souza
  • Anderson João Simione
  • Sarah Emanuelle Viana Campos
  • Dr Fernando Barroso Pos Graduaçao de cirurgia da UFC

DOI:

https://doi.org/10.46765/2675-374X.2023v4n2p198

Abstract

The allogeneic hematopoietic stem cell transplant (allo-HCT) represents an important therapeutic strategy for acute leukemias, lymphomas and solid neoplasms, also used in benign diseases, such as aplastic anemia and inborn errors of immunity. This treatment requires myeloablative chemotherapy (conditioning regimen) followed by the infusion of donor-derived hematopoietic stem cells. However, this procedure carries some risks, such as infections, graft versus host disease (GVHD) and conditioning toxicity, which  may result in transplant-related mortality. Over the decades, due to the increasing life expectancy and new advances in medicine,  the cases of patients > 50 years with hematologic diseases that need allogeneic transplant  have grown, requiring a comprehensive geriatric assessment as a mechanism for  the best treatment option choice.

Objective: To apply a clinical frailty score and Karnofsky score in allogeneic hematopoietic stem cell older than 50 years old for three years in Walter Cantídio University Hospital (Fortaleza/Ceará) and in Amaral Carvalho Hospital (Jaú/São Paulo), expecting to recognize the profile of this patients and to demonstrate the relation between the clinical frailty score and overall survived, besides to estimate the contribution of GVHD prophylaxis and relapse in overall survival. Methods: Multicentric, retrospective, descriptive, analytical and quantitative study, acquiring dates by means of exams and medical record from Walter Cantídio University Hospital in Fortaleza/Ceará and Amaral Carvalho Hospital in Jaú/São Paulo. Results: The study selected 252 patients, 147 males and 105 females, sort in gender, disease, HCTCI score, CFS and KPS. In three years, the overall survival in FIT score is 2,46 years, while in FRAILTY score is 1,82 years. About the prophylaxis, the combination of cyclosporine, mycophenolate mofetil, cyclophosphamide had worse results than others prophylaxis. As expected, in case of relapse, there is shorter survival. Conclusion: The elderly population require a geriatric score in order to evaluate the profile of this patients once the allogeneic transplant must happen, then FIT patients has longer survival than FRAILTY patients.

Author Biography

Dr Fernando Barroso, Pos Graduaçao de cirurgia da UFC

Pos Graduaçao de cirurgia da UFC

Downloads

Published

06/02/2023

How to Cite

Lima, Y. C. e S. F., Araujo Duarte, B., Barroso Duarte Filho, F., Araujo Duarte, I., Araujo Duarte, J. V. ., Ferrari dos Santos, A. C., … Barroso Duarte, F. (2023). ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS IN BRAZIL : A COHORT. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 4(2), 198. https://doi.org/10.46765/2675-374X.2023v4n2p198

Issue

Vol. 4 No. 2 (2023): JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY

Section

Original article

License

Copyright (c) 2022 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

License and Copyright Policy

The Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT) adopts an open access policy, ensuring that all published articles are freely available to the public without restrictions.

  1. License

    • All articles published in JBMTCT are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
    • This license permits anyone to:
      • Share: Copy and redistribute the material in any medium or format.
      • Adapt: Remix, transform, and build upon the material for any purpose, even commercially.
    • The only requirement is that appropriate credit is given to the original authors and source, a link to the license is provided, and any changes made are indicated.

    More information about the license can be found here: Creative Commons Attribution 4.0 International License.

  2. Authors’ Rights

    • Authors retain the copyright to their work.
    • Authors grant JBMTCT the right to publish the work and make it openly accessible online.
    • Authors are free to:
      • Distribute the published version of their article (e.g., post it on personal websites or institutional repositories).
      • Use the article in future works, presentations, or derivative publications, as long as the original publication in JBMTCT is properly acknowledged.

  3. No Embargo

    • There is no embargo period; articles are made freely available immediately upon publication.

  4. Ethical Use

    • Users of JBMTCT articles must ensure proper citation of the authors and the journal.
    • Articles must not be used in ways that violate ethical or legal standards.

  5. Disclaimer

    • While JBMTCT aims to ensure the accuracy and reliability of published content, the journal and its editors are not responsible for the consequences of its use.

For any questions regarding our licensing terms, please contact us at: journalbmtct@sbtmo.org.br 

JBMTCT is committed to the principles of open access to advance knowledge and scientific collaboration.

 

Most read articles by the same author(s)

<< < 1 2 3 > >>